Janney Montgomery Scott LLC decreased its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Get Rating) by 1.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,711 shares of the biotechnology company’s stock after selling 147 shares during the period. Janney Montgomery Scott LLC’s holdings in Axon Enterprise were worth $1,240,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of the stock. Artemis Investment Management LLP boosted its position in shares of Axon Enterprise by 6.2% during the 3rd quarter. Artemis Investment Management LLP now owns 366,238 shares of the biotechnology company’s stock valued at $42,421,000 after purchasing an additional 21,346 shares in the last quarter. Calamos Advisors LLC boosted its position in shares of Axon Enterprise by 113.3% during the 3rd quarter. Calamos Advisors LLC now owns 20,133 shares of the biotechnology company’s stock valued at $2,330,000 after purchasing an additional 10,693 shares in the last quarter. Whittier Trust Co. of Nevada Inc. bought a new position in shares of Axon Enterprise during the 3rd quarter valued at about $90,000. Louisiana State Employees Retirement System bought a new position in shares of Axon Enterprise during the 3rd quarter valued at about $2,084,000. Finally, WCM Investment Management LLC boosted its holdings in shares of Axon Enterprise by 0.9% in the third quarter. WCM Investment Management LLC now owns 137,256 shares of the biotechnology company’s stock worth $15,669,000 after buying an additional 1,236 shares during the period. Institutional investors and hedge funds own 75.62% of the company’s stock.
Insider Activity at Axon Enterprise
In related news, COO Joshua Isner sold 275 shares of the firm’s stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $177.96, for a total transaction of $48,939.00. Following the transaction, the chief operating officer now owns 237,576 shares of the company’s stock, valued at $42,279,024.96. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, Director Matthew R. Mcbrady sold 1,699 shares of Axon Enterprise stock in a transaction that occurred on Friday, November 11th. The shares were sold at an average price of $182.88, for a total value of $310,713.12. Following the transaction, the director now owns 5,651 shares of the company’s stock, valued at $1,033,454.88. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, COO Joshua Isner sold 275 shares of Axon Enterprise stock in a transaction that occurred on Thursday, December 1st. The shares were sold at an average price of $177.96, for a total transaction of $48,939.00. Following the completion of the transaction, the chief operating officer now directly owns 237,576 shares in the company, valued at approximately $42,279,024.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,093 shares of company stock valued at $4,048,446. 6.90% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
Axon Enterprise Price Performance
Shares of AXON opened at $184.47 on Wednesday. The firm has a market cap of $13.13 billion, a PE ratio of 127.22 and a beta of 0.79. The firm’s 50 day moving average price is $177.16 and its 200 day moving average price is $143.71. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.39 and a current ratio of 2.79. Axon Enterprise, Inc. has a twelve month low of $82.49 and a twelve month high of $193.85.
Axon Enterprise (NASDAQ:AXON – Get Rating) last issued its quarterly earnings data on Tuesday, November 8th. The biotechnology company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.24. The firm had revenue of $311.75 million for the quarter, compared to analyst estimates of $276.99 million. Axon Enterprise had a net margin of 9.75% and a return on equity of 9.88%. As a group, research analysts expect that Axon Enterprise, Inc. will post 0.54 EPS for the current fiscal year.
Axon Enterprise Profile
Axon Enterprise, Inc engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services.
- Get a free copy of the StockNews.com research report on Axon Enterprise (AXON)
- Can Alaska Air Continue Soaring Above The Airline Industry?
- Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
- Insulet Has Potential To Gain More Than Analysts Are Forecasting
- Cathie Wood Is Buying These Stocks, Should You?
- Thor Industries Hammered Its Numbers. Is it a Buy?
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.